171 related articles for article (PubMed ID: 22289890)
61. Role of Local Radiation Therapy in Cancer Immunotherapy.
Demaria S; Golden EB; Formenti SC
JAMA Oncol; 2015 Dec; 1(9):1325-32. PubMed ID: 26270858
[TBL] [Abstract][Full Text] [Related]
62. Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor.
Wang L; Yi Y; Yin D; Zhou Z; Fan J; Ye W; Zhao W
Cytotherapy; 2016 Apr; 18(4):581-9. PubMed ID: 26971686
[TBL] [Abstract][Full Text] [Related]
63. Bioluminescence imaging: looking beyond the light.
Keyaerts M; Caveliers V; Lahoutte T
Trends Mol Med; 2012 Mar; 18(3):164-72. PubMed ID: 22321645
[TBL] [Abstract][Full Text] [Related]
64. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
Chester C; Marabelle A; Houot R; Kohrt HE
Curr Opin Immunol; 2015 Apr; 33():1-8. PubMed ID: 25576932
[TBL] [Abstract][Full Text] [Related]
65. Portable bioluminescent platform for in vivo monitoring of biological processes in non-transgenic animals.
Yevtodiyenko A; Bazhin A; Khodakivskyi P; Godinat A; Budin G; Maric T; Pietramaggiori G; Scherer SS; Kunchulia M; Eppeldauer G; Polyakov SV; Francis KP; Bryan JN; Goun EA
Nat Commun; 2021 May; 12(1):2680. PubMed ID: 33976191
[TBL] [Abstract][Full Text] [Related]
66. Application of a new wall-less plate technology to complex multistep cell-based investigations using suspension cells.
Quiñones GA; Moore TI; Nicholes K; Lee H; Kim S; Sun L; Jeon NL; Stephan JP
Blood; 2013 Feb; 121(7):e25-33. PubMed ID: 23255559
[TBL] [Abstract][Full Text] [Related]
67. Immunosurveillance and immunotherapy of tumors by innate immune cells.
Iannello A; Thompson TW; Ardolino M; Marcus A; Raulet DH
Curr Opin Immunol; 2016 Feb; 38():52-8. PubMed ID: 26686774
[TBL] [Abstract][Full Text] [Related]
68. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Fujiwara Y; Sun Y; Torphy RJ; He J; Yanaga K; Edil BH; Schulick RD; Zhu Y
Cancer Res; 2018 Dec; 78(23):6655-6665. PubMed ID: 30315115
[TBL] [Abstract][Full Text] [Related]
69. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
[TBL] [Abstract][Full Text] [Related]
70. Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation.
Zhang GJ; Chen TB; Bednar B; Connolly BM; Hargreaves R; Sur C; Williams DL
Neoplasia; 2007 Aug; 9(8):652-61. PubMed ID: 17786184
[TBL] [Abstract][Full Text] [Related]
71. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
72. Cooperativity of adaptive and innate immunity: implications for cancer therapy.
Shanker A; Marincola FM
Cancer Immunol Immunother; 2011 Aug; 60(8):1061-74. PubMed ID: 21656157
[TBL] [Abstract][Full Text] [Related]
73. Modeling selective elimination of quiescent cancer cells from bone marrow.
Cavnar SP; Rickelmann AD; Meguiar KF; Xiao A; Dosch J; Leung BM; Cai Lesher-Perez S; Chitta S; Luker KE; Takayama S; Luker GD
Neoplasia; 2015 Aug; 17(8):625-33. PubMed ID: 26408255
[TBL] [Abstract][Full Text] [Related]
74. The inducers of immunogenic cell death for tumor immunotherapy.
Li X
Tumori; 2018; 104(1):1-8. PubMed ID: 28967094
[TBL] [Abstract][Full Text] [Related]
75. Highly Bright NIR-BRET System for Imaging Molecular Events in Live Cells.
Nishihara R; Suzuki K; Kim SB; Paulmurugan R
Methods Mol Biol; 2021; 2274():247-259. PubMed ID: 34050477
[TBL] [Abstract][Full Text] [Related]
76. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
77. Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy.
Inoue Y; Izawa K; Tojo A; Nomura Y; Sekine R; Oyaizu N; Ohtomo K
Exp Hematol; 2007 Mar; 35(3):407-15. PubMed ID: 17309821
[TBL] [Abstract][Full Text] [Related]
78. Tissue Site and the Cancer Immunity Cycle.
Horton BL; Fessenden TB; Spranger S
Trends Cancer; 2019 Oct; 5(10):593-603. PubMed ID: 31706507
[TBL] [Abstract][Full Text] [Related]
79. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
80. Harnessing innate immunity in cancer therapy.
Demaria O; Cornen S; Daëron M; Morel Y; Medzhitov R; Vivier E
Nature; 2019 Oct; 574(7776):45-56. PubMed ID: 31578484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
